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Abstract
Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous disease affecting the epithelium of the oral
cavity, pharynx and larynx. Conditions of most patients are diagnosed at late stages of the disease, and no sen-
sitive and specific predictors of aggressive behavior have been identified yet. Therefore, early detection and prog-
nostic biomarkers are highly desirable for a more rational management of the disease. Hypermethylation of CpG
islands is one of the most important epigenetic mechanisms that leads to gene silencing in tumors and has been
extensively used for the identification of biomarkers. In this study, we combined rapid subtractive hybridization and
microarray analysis in a hierarchical manner to select genes that are putatively reactivated by the demethylating
agent 5-aza-2′-deoxycytidine (5Aza-dC) in HNSCC cell lines (FaDu, UM-SCC-14A, UM-SCC-17A, UM-SCC-38A). This
combined analysis identified 78 genes, 35 of which were reactivated in at least 2 cell lines and harbored a CpG
island at their 5′ region. Reactivation of 3 of these 35 genes (CRABP2, MX1, and SLC15A3) was confirmed by
quantitative real-time polymerase chain reaction (PCR; fold change, ≥3). Bisulfite sequencing of their CpG islands
Abbreviations: 5Aza-dC, 5-aza-2′-deoxycytidine; HNSCC, head and neck squamous cell carcinoma; MSP, methylation-specific polymerase chain reaction; qRT-PCR, quanti-
tative real-time polymerase chain reaction; RaSH, rapid subtractive hybridization; TSS, transcription start site; TMA, tissue microarray
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revealed that they are indeed differentially methylated in the HNSCC cell lines. Using methylation-specific PCR, we
detected a higher frequency of CRABP2 (58.1% for region 1) andMX1 (46.3%) hypermethylation in primary HNSCC
when compared with lymphocytes from healthy individuals. Finally, absence of the CRABP2 protein was associ-
ated with decreased disease-free survival rates, supporting a potential use of CRABP2 expression as a prognostic
biomarker for HNSCC patients.
Neoplasia (2009) 11, 1329–1339
Introduction
Head and neck squamous cell carcinoma (HNSCC) comprises a het-
erogeneous disease, which arises from the epithelium of the oral cav-
ity, pharynx, and larynx [1], and is associated with tobacco and
alcohol abuse [2]. According to worldwide cancer statistics, approx-
imately 450,000 new oral and laryngeal carcinomas are diagnosed
annually, and the incidence varies between countries, probably as a
result of environmental risk factors [3]. For example, the incidence
rates for oral cancer in males are high in France and comparatively
low in the United States and Brazil [4–6].
Although detection of HNSCC in early stages improves the sur-
vival rate, most patients present advanced stages of the disease at the
time of diagnosis, and no sensitive and specific predictors of aggres-
sive behavior have been identified. Lymph node status is still the
most powerful prognostic factor, but the routine histopathologic ex-
amination of neck dissection specimens is unable to detect all micro-
metastases [7]. Therefore, the identification of early detection and
prognostic biomarkers is highly desirable for planning an efficient
and appropriate treatment procedure.
Evidence for a fundamental role for epigenetic modifications in
head and neck cancer cells has been widely reported in the literature,
including DNAmethylation and histone deacetylation [8,9]. Both pro-
moter hypermethylation of specific genes [10–12] and global hypo-
methylation are implicated in head and neck tumorigenesis [13,14].
Aberrant DNA methylation, such as regional gains or global loss,
is an early event that occurs as a nonrandom signature in almost all
tumors [15] and may be used for the identification of biomarkers.
Strategies for assessing genome-wide methylation changes include ge-
nomic scanning after methylation-specific cleavage of the DNA and
two-dimensional electrophoresis, amplification of intermethylated
sites by arbitrarily primed polymerase chain reaction (PCR), and
microarray gene expression analysis after treatment with DNA de-
methylating agents such as the DNA methyltransferase inhibitor 5-
aza-2′-deoxycytidine (5Aza-dC) [16,17]. 5Aza-dC is incorporated
into genomic DNA during replication, where it acts as an irreversible
inhibitor of methyltransferase by forming a covalent complex with
methyltransferase active sites. This suicide inhibition depletes meth-
yltransferase activity, resulting in generalized DNA demethylation
and release of specific genes from methylation-mediated transcrip-
tional silencing [18].
In the present study, we carried out a genome-wide screening of
5Aza-dC–reactivated genes in four human squamous cell carcinoma
cell lines derived from different topographical sites, using a combina-
tion of rapid subtractive hybridization (RaSH) and complementary
DNA (cDNA) microarray analysis. This analysis revealed two genes
reactivated by 5Aza-dC (CRABP2 and MX1), and they were fre-
quently hypermethylated in primary HNSCCs. Furthermore, the ab-
sence of CRABP2 protein was associated with decreased disease-free
survival rates, supporting a potential use of CRABP2 expression as a
prognostic biomarker for HNSCC.
Materials and Methods
Tumor Cell Lines and 5Aza-dC Treatment
Four HNSCC cell lines derived from distinct topographical sites,
pharynx (FaDu), floor of the mouth (UM-SCC-14A), supraglottis
(UM-SCC-17A), and tonsil (UM-SCC-38A), were used in this study.
UM-SCC-14A, UM-SCC-17A, and UM-SCC-38A cell lines were
kindly provided byDr. Thomas E. Carey of the University ofMichigan,
USA, and FaDu (HTB-43) was purchased fromAmericanType Culture
Collection (ATCC,Manassas, VA). Cell lines were routinely cultured as
monolayers in minimum essential medium (Eagle) supplemented with
10% fetal calf serum, 1% L-glutamine, and 1% penicillin/streptomycin,
at 37°C and 5% carbon dioxide. Cells were seeded at a density of
106 cells/10-cm dish, cultured for 48 hours, and treated for 4 days with
freshly prepared 2.5 μM 5Aza-dC (Sigma, St Louis, MO) dissolved in
50% acetic acid.
Tumor Samples
For methylation-specific PCR (MSP) analysis, 140 HNSCC sam-
ples and 10 lymphocyte samples from normal individuals were used.
The samples were obtained from the Tumor Tissue Biobank of the
Medical and Research Center – A.C. Camargo Hospital, São Paulo,
and from the Head and Neck Genome Project/Gencapo – Brazil
after Institutional Ethics Committee approval. Tumor samples were
microdissected to enrich for tumor cells. Five-micrometer-thick sec-
tions from the frozen tumors were cut onto glass slides, fixed, and
stained with hematoxylin and eosin. The hematoxylin and eosin–
stained section was used as a guide for manual dissection, and only
samples with more than 70% of tumor area were used in this study.
All samples were reviewed by two independent pathologists. The
main clinicopathological characteristics corresponding to these sam-
ples are shown in Table W3. None of the patients received preoper-
ative treatment, and 41.3%, 42.0%, and 16.7% of patients were
treated by surgery alone, surgery + radiotherapy, or surgery + radio-
therapy + chemotherapy, respectively. The mean follow-up for these
patients was approximately 31 months.
For the tissue microarray (TMA) analysis, an independent set of
75 HNSCC samples was used. These samples were obtained from
the archives of the Department of Anatomic Pathology, A.C. Camargo
Hospital, São Paulo, Brazil, and were reviewed by two independent
pathologists. The main clinicopathological characteristics correspond-
ing to these samples are also shown in Table W3. None of the
patients received preoperative treatment, and 41.3%, 42.0%, and
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6.7% of patients were treated by surgery alone, surgery + radiotherapy,
or surgery + radiotherapy + chemotherapy, respectively. The average
follow-up period was approximately 56 months.
DNA and RNA Extraction
Genomic DNA from tumor cell lines was purified using a Super
Quick Gene DNA Isolation kit (Analytical Genetic Testing Center)
following the protocol instructions. Total RNA was isolated using
TRIzol Reagent for Molecular Biology (Invitrogen/Life Technologies,
Carlsbad, CA). Genomic DNA from tumor samples was purified by
standard phenol/chloroform purification. DNA quality was verified
by electrophoresis through agarose gel on visualization with ethidium
bromide. For microarray experiment, total RNA was further purified
using the RNeasy Mini Kit (Qiagen, Valencia, CA). For quantitative
real-time PCR (qRT-PCR), 5 μg of total RNA was previously treated
with the RQ1 RNase-free DNase (Promega, Madison,WI). The RNA
integrity after the purification procedure was evaluated using the
Agilent 2100-Bioanalyser revealing a minimal RIN value of 7.9.
Rapid Subtractive Hybridization
RaSH cDNA libraries were prepared by a modified protocol taken
from Jiang et al. [19]. The cDNA were initially digested with Mbol
(Gibco, Gaithersburg, MD) at 37°C for 1 hour. The fragments were
inserted into XhoI-digested pZERO plasmid (1 μg/μl) at 16°C for
3 hours. The constructs were introduced into the DH10-B competent
cells. Two RaSH cDNA libraries were prepared: one using cDNA from
the FaDu cell line treated with 5Aza-dC as tester and the mock-treated
FaDu cell line as driver and the other using cDNA from the mock-
treated FaDu cell line as tester and cDNA from the FaDu cell line
treated with 5Aza-dC as driver.
Bacterial colonies were selected randomly and PCR amplified,
using M13 forward and reverse primers. Inserts were sequenced
with forward and reverse M13 primers using a DYEnamic ET Dye
Terminator Sequencing kit (Amersham Biosciences, Piscataway, NJ)
and a MegaBACE 1000 sequencer (Amersham Biosciences). The se-
quences were analyzed, using an annotation pipeline that consists
of four steps: 1) quality checking, phred base-calling, cutoff 0.05
[20,21]; 2) vector trimming and removal of undesirable sequences
such as bacterial, mitochondrial, and rRNA sequences; 3) masking of
repetitive elements and screening of low-complexity regions by Re-
peat Masker, using the default settings [22]; and 4) annotation against
existing databases, using BLASTN with default parameters. Signifi-
cant hits were determined by using an E-value threshold of 10−15 for
searches against nucleotide sequence databases [23].
cDNA Microarray
A total of 151 RaSH cDNA clones were amplified by PCR, puri-
fied, and spotted onto glass slides (Corning, Corning, NY) with a Flexys
Robot (Genomic Solutions, Ann Arbor, MI). A total of 2352 spots,
including 151 RaSH cDNA clones, 496 negative controls (pure H2O
or DMSO), 48 positive controls (Q gene fragment from phage lambda),
and 1657 cDNA fragments derived from other projects were arranged
on this customized cDNA platform. Positive hybridization signals
from all spots were considered for evaluation of hybridization quality,
normalization, and statistical analysis. However, for the purpose of this
study, only differences in the expression levels of RaSH cDNA clones
were used.
Total RNA extracted from HNSCC cell lines was further purified
using the RNeasy Mini Kit (Qiagen) before the RNA amplification
procedure. A two-round RNA amplification procedure was carried
out as previously described [24]. Amplified RNA was used in a re-
verse transcription reaction in the presence of random hexamer primer
(Invitrogen/Life Technologies), Cy3- or Cy5-labeled dCTP (Amersham
Biosciences), and SuperScript II (Invitrogen/Life Technologies). Equal
amounts of Cy3- or Cy5-labeled cDNA derived from cell lines treated
or not with 5Aza-dC were mixed and cohybridized to the custom-
ized platform. Dye swap was performed, and hybridizations were car-
ried out in duplicates, resulting in four independent hybridizations
for each cell line. Self-self hybridization experiments were performed
by pooling the cDNA derived from the four untreated cell lines, la-
beling them with Cy3 and Cy5 independently. Labeled cDNA were
then cohybridized to the customized platform. Dye swap was also
performed, and hybridizations were carried out in duplicates, result-
ing in four independent hybridizations for self-self experiments. Ar-
rays were scanned and extracted as previously described [25]. Self-self
experiments–based statistical test for low-replication microarray stud-
ies was performed to select genes reactivated by 5Aza-dC treatment.
This strategy has been used to derive intensity-dependent cutoffs to
classify a gene as differentially expressed in microarray studies [26].
The cutoff for all comparisons between treated and untreated sam-
ples was 99%.
Selection of Genes for Validation by qRT-PCR
Genes that were reactivated by 5Aza-dC in at least two of the four
cell lines and that possessed a CpG island in their 5′ region were
selected for qRT-PCR validation. Genomic sequences corresponding
to 5′ regions of reactivated genes were analyzed for the presence of a
CpG island using the UCSC Genome Browser (http://genome.ucsc.
edu/). Criterion for a CpG island was based on those of Gardiner-
Garden and Frommer [27], as a GC content of 50% or greater, length
greater than 200 bp, and a ratio greater than 0.6 of the observed
number of CG dinucleotides to the expected number for the total
number of Gs and Cs in the segment. Repeat Masker (ftp.genome.
washington.edu/cgi-bin/Repeat-Masker) was used to determine whether
selected CpG islands contained repetitive elements.
Quantitative Real-time Polymerase Chain Reaction
qRT-PCR amplification was performed with Power SYBR Green
and an ABI 7500 Real-time PCR System (Applied Biosystems, Foster
City, CA). The PCR total volume was 20.0 μl containing 10.0 μl of
PCR Power SYBR Green Master Mix, 2.0 μl of diluted cDNA, and
optimized primer concentrations for each primer pair (Table W4).
Conditions were set as an initial polymerase activation step for 2 min-
utes at 50°C and 10 minutes at 95°C, followed by 40 cycles of 15 sec-
onds at 95°C for template denaturation, 1 minute at 60°C for
extension and fluorescence measurement. Afterward, a dissociation
protocol was used for each primer pair to verify the specificity of the
qRT-PCR reaction and the absence of primer dimer. All samples were
amplified in triplicates and the mean was used for qRT-PCR analysis,
and a no-template control was also included. Primers were located in
different exons and designed for optimal hybridization kinetics with
Primer Express 2.0 (Applied Biosystems). Relative quantification of
gene expression was carried out with the mathematical model devel-
oped by Pfaffl [28]. All PCR efficiencies were greater than 95%. Non-
treated cell lines were used as reference samples, andTUBA1C (TUBA6 )
was selected as endogenous control gene after GeNorm [29].
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Bisulfite Sequencing
Genomic DNAwas subjected to sodium bisulfite treatment to mod-
ify unmethylated cytosine to uracil, as previously described [30]. Hyper-
methylation in HNSCC cell lines was determined by the bisulfite
sequencing. Bisulfite-treated DNAwas amplified by a nested-PCR pro-
tocol, using primers designed to amplify CpG-rich regions located at
the 5′ regions of CRABP2 (−450 to −117 relative to transcription start
site [TSS] encompassing 22CpG dinucleotides),MX1 (−71 to +845 rel-
ative to TSS encompassing 78 CpG dinucleotides), and SLC15A3
(+351 to +845 relative to TSS encompassing 58 CpG dinucleotides;
Figure 2). Primer sequences and PCR amplification conditions are avail-
able on request. Amplified products were cloned using the InsTAclone
PCRCloning Kit (Fermentas, Hanover, MD). Five positive clones were
sequenced for each cell line using the Big Dye Terminator v3.1 Cycle
Sequencing kit and an ABI3130 sequencer, in accordance withmanufac-
turer’s instructions (Applied Biosystems). The methylation percentage
for each sample was calculated as the proportion of unconverted CpG
dinucleotides among all the CpGs analyzed in all five positive clones.
Methylation-Specific PCR
Hypermethylation in head and neck tumors was determined by
the MSP method as reported by Herman et al. [30], but amplified
fragments were analyzed on silver-stained 8% polyacrylamide gels.
Bisulfite-modified DNA was PCR amplified with primers specific
for methylated versus unmethylated DNA. Two primer pairs were de-
signed for MSP analysis of the CRABP2 gene, and a single primer
pair was used for the MX1 gene, as indicated in Figure 2. Primer
sequences and PCR amplification conditions are available on request.
Tissue Microarray
To construct the TMA, core biopsies were taken from previously
defined areas, with a Tissue Microarrayer (Beecher Instruments, Silver
Springs, MD). Tissue cores with a dimension of 1.0 mm were punched
from each specimen and arrayed in duplicate on a recipient paraffin
block. Each core was spaced 0.2 mm apart. After cutting (3 μm) on
the recipient block and transferring with an adhesive tape to coated
slides for subsequent UV cross-linkage (Instrumedics Inc, Hackensack,
NJ), the slides were dipped in a layer of paraffin to prevent oxidation
and kept in a −20°C freezer.
For immunostaining, the sections were deparaffinized and rehy-
drated in graded ethanol solutions, treated with peroxide to quench
endogenous peroxidase (0.3% H2O2 for 15 min), and blocked for
avidin/biotin (Biotin Blocking System; DAKO, Carpinteria, CA) and
for protein (Protein Block Serum-Free; DAKO). Antigenic recovery
was performedbywet heating in a pressure cooker. Slides were incubated
with anti-CRABP2 (MAB5488, 1:2000; Chemicon, Inc, Temecula,
CA). The immunohistochemical reaction was carried out in duplicate
at differentTMA levels, representing four-fold redundancy for each case.
Positive and negative controls were included in all reactions. Positive
controls were obtained using normal breast slides incubated with the
CRABP2 antibody. CRABP2 binding was assessed by two kinds of neg-
ative controls: 1) omitting the primary antibody and incubating slides
with phosphate-buffered saline; 2) replacing the primary antibody with
normal mouse serum.
After scanning each tumor specimen in low power field to choose
the most stained area, at least five fields were evaluated under high
power. The presence of a clearly visible dark brown precipitation was
considered an immunoreaction. Evaluation of CRABP2 included the
proportion of reactive cells within the tumors and the staining inten-
sity. The proportion score described the fraction of positively stained
tumor cells (<10% of positive cells; ≥10% of tumors cells stained).
The immunostaining intensities were assessed visually by two pa-
thologists using blind analysis by determining the color intensity of
stained cells. The samples were classified as negative (no visible reac-
tion or positivity in <10% of positive cells) or positive reaction (weak
and strongly positive present in ≥10% of tumors cells stained). For
statistical analysis, the samples were categorized into two groups: neg-
ative and weakly/strongly positive cases.
Statistical Analysis
For frequency analysis in contingency tables, statistical analyses of
associations between variables were performed by the χ 2 test or Fisher’s
exact test (with significance set at P < .05). The overall survival was
defined as the interval between the beginning of treatment and the
date of death or the last information for censored observations. The
disease-free interval was measured from the date of the treatment to
the date when locoregional recurrence or distant metastasis was di-
agnosed. Overall survival and disease-free survival probabilities were
estimated by the Kaplan-Meier method, and the log-rank test was
applied to assess the significance of differences among actuarial sur-
vival curves. Multivariate analysis was carried out using Cox pro-
portional hazards model (stepwise forward selection). All variables
presenting P < .20 on the univariate analysis were selected for build-
ing a multiple model. For all tests, type I error (α) was established
as 0.05, and results were considered statistically significant when P <
.05. All statistical analyses were performed with the STATA soft-
ware (Intercooled Stata release 7.0; Stata Corporation, College Sta-
tion, TX).
Results
Identification of Genes Reactivated by 5Aza-dC
To identify novel methylation-silenced genes in HNSCC cell lines,
we treated the FaDu cell line with the demethylating agent 5Aza-dC
and used a combination of RaSH and cDNA microarray analysis to
identify genes reactivated on treatment. Initially, two RaSH cDNA
libraries were constructed: one using cDNA prepared from the FaDu
cell line treated with 5Aza-dC as tester and the mock-treated FaDu
cell line as driver (5Aza-dC tester library) and the other using cDNA
prepared from mock-treated FaDu cell line as tester and cDNA from
the FaDu cell line treated with 5Aza-dC as driver (mock tester li-
brary; Figure 1). A total of 1773 cDNA clones were sequenced, cor-
responding to 876 and 897 clones derived from the 5Aza-dC tester
and mock tester libraries, respectively. After similarity searches in
public databases, we found that these sequences correspond to 415
known genes of which 65 were present in both RaSH libraries. A
total of 181 and 169 genes were found exclusively in the 5Aza-dC
tester and mock tester libraries, respectively. Of the 181 cDNA
clones reactivated by the 5Aza-dC, 151 were successfully amplified
and spotted onto glass slides (Figure 1; Table W1).
Microarray analysis was then carried out with RNA extracted from
FaDu and three additional HNSCC cell lines (UM-SCC-14A, UM-
SCC-17A, and UM-SCC-38A) derived from distinct topographical
sites and treated with 5Aza-dC. Self-self experiments based on a sta-
tistical test for low-replication microarray studies were performed to
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identify genes reactivated on treatment. A total of 78 reactivated genes
were identified using this combined approach, of which 31, 18, 47,
and 46 were identified in the FaDu, UM-SCC-14A, UM-SCC-17A,
and UM-SCC-38A cell lines, respectively. A total of 48 genes were
reactivated in at least two cell lines and used for further investiga-
tion. We reasoned that commonly reactivated genes, inactivated in
at least two HNSCC, were more likely to represent genes frequently
inactivated in tumors.
Validation Analysis by qRT-PCR of Genes Reactivated by
5Aza-dC in HNSCC Cell Lines
Of the 48 genes selected by the microarray analysis, 35 harbored a
bona fide CpG island in the 5′ region and were further selected for
qRT-PCR quantification of gene expression in the same cell lines
used in the microarray analysis (Table W2). Three genes (CRABP2,
MX1, and SLC15A3) were confirmed to be reactivated at least three-
fold in at least one of the cell lines after 5Aza-dC treatment. All these
genes were upregulated in the FaDu cell line. In addition, the CRABP2
and MX1 genes were also upregulated in the UM-SCC-14A and UM-
SCC-38A cell lines, respectively (Table 1).
DNA Methylation Analysis in HNSCC Cell Lines
The methylation status of the CpG island at the 5′ region site of
the CRABP2, MX1, and SLC15A3 genes was then investigated by
bisulfite sequencing in HNSCC cell lines that showed induction of
gene expression after 5Aza-dC treatment.
A significant reduction in the global methylation level (from
40.00% to 5.50%) of the 5′ region of CRABP2 was observed in
the FaDu cell line after treatment with the demethylating agent,
which is in agreement with the 4.6-fold increase in the CRABP2 mes-
senger RNA (mRNA) level observed in this cell line treated with
5Aza-dC. Corroborating this result (Figure 2), reduction in the meth-
ylation levels was observed for almost all CpG dinucleotides analyzed.
A less pronounced reduction in the DNA methylation level of the
MX1 5′ region was observed in the FaDu (from 27.70% to 12.70%)
and UM-SCC-14A (from 7.80% to 1.02%) cell lines (Figure 2). The
reduction was limited to dinucleotides 39 to 56 located within the first
exon of the MX1 gene. Reduction in the methylation levels of these
specific dinucleotides was directly correlated with induction of gene ex-
pression on treatment observed in these cell lines, as measured by qRT-
PCR (22.4-fold for FaDu and 4.5-fold for UM-SCC-14A), suggesting
that these dinucleotides play a critical role in transcription regulation.
In the case of SLC15A3 gene, an increase of 7.3- and 3.0-fold in
its expression level was observed in the FaDu and UM-SCC-38A cell
lines, respectively. However, a significant reduction (from 96.6% to
5.5%) in the DNA methylation level of the SLC15A3 5′ region was
exclusively observed in the UM-SCC-38A cell line. These results
suggest that other epigenetic mechanisms, such as histone modifica-
tion, may also play a critical role in regulating the expression of the
SLC15A3 gene.
DNA Methylation Analysis in Primary HNSCC
We next sought to determine whether CRABP2 and MX1 hyper-
methylation, identified in the preceding experiments using cell lines,
was also present in primary HNSCC. The methylation status of
SLC15A3 was not further investigated in primary tumors because
Figure 1. Flowchart for the identification of differentially methylated
genes in HNSCC cell lines. FaDu cell line was treated with 5Aza-dC,
and purified mRNA was used to construct RaSH cDNA libraries. A
set of 151 nonredundant genes was used to prepare an enriched
cDNA platform for microarray analysis. A total of 48 genes were re-
activated in at least two cell lines. From them, 35 genes harboring a
CpG island located at their 5′ region were submitted to qRT-PCR.
Up-regulation of gene expression by 5Aza-dC was confirmed for
three genes. Bisulfite sequencing revealed three differentially meth-
ylated genes.
Table 1. Validation of Gene Expression Reactivation by Microarray Analysis and qRT-PCR in 5Aza-dC–Treated HNSCC Cell Lines.
Official Symbol Microarray qRT-PCR (Fold Change)
FaDu UM-SCC-14A UM-SCC-17A UM-SCC-38A FaDu UM-SCC-14A UM-SCC-17A UM-SCC-38A
CRABP2 Up Up Up — 4.6 1.9 1.7 ND
MX1 Up Up — Up 22.4 4.5 ND 0.2
SLC15A3 Up Up Up Up 7.3 2.2 1.0 3.0
ND indicates not determined; Up, upregulated.
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Figure 2. A representative result of bisulfite sequencing. Each panel represents a schematic representation of the genome structure of
each gene including their 5′ CpG islands. Exons and untranslated regions are represented by filled or open boxes, respectively. The
transcription initiation site is represented by +1. Expanded view shows the position of CpG islands and the region analyzed by bisulfite
sequencing. Vertical marks represent individual CpG dinucleotides and their spacing accurately reflects the CpG density of the region.
MSP primers are represented by horizontal arrows in the panels. Primer sets M and U were designed for the same CpG dinucleotide
(indicated by an asterisk). Methylation profiles of the treated (5Aza-dC) and untreated (mock) cell lines are indicated in the lower part
of the panels. Each row represents one sequenced clone, and open and filled circles represent unmethylated and methylated CpG di-
nucleotides, respectively. (A) Bisulfite sequencing of CRABP2 in the FaDu cell line. (B) Bisulfite sequencing of MX1 in the FaDu and
UM-SCC-14A cell lines. (C) Bisulfite sequencing of SLC15A3 in the FaDu and UM-SCC-38A cell lines.
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we were unable to detect a direct correlation between DNA methyl-
ation level and gene expression. MSP analysis of CRABP2 and MX1
was carried out in 140 HNSCC samples and 10 lymphocyte sam-
ples from normal individuals. The main clinicopathological charac-
teristics of the HNSCC patients are shown in supplementary data
(Table W3), and representative MSP results are shown in Figure 3.
MSP primers were designed to target the most frequently methylated
CpG dinucleotides and those with a direct correlation with mRNA
expression as revealed by bisulfite sequencing of the tumor cell lines.
Two primer pairs were designed for MSP analysis of the CRABP2 (one
pair for region 1 – R1 and one pair for region 2 – R2) and a single
primer pair was used for the MX1 gene, as indicated in Figure 2.
CRABP2 hypermethylation was detected in 56.4% (79/140) of
the samples when primers for R1 were used and in 10.0% (14/
140) of the samples when reactions were carried out with R2 prim-
ers. For 13 patients (9.3%), hypermethylation was detected with
both primer pairs. No CRABP2 hypermethylation was detected in
normal lymphocytes for both primer pairs. We then investigated the
association between CRABP2 hypermethylation and well-established
clinicopathological parameters used for HNSCC. As shown in Table 2,
Figure 3.MSP analysis of CRABP2 and MX1 genes. Representative results of MSP analysis of CRABP2 and MX1 genes in the FaDu cell
line and five different HNSCC samples. Methylated tumors are indicated with asterisks. The lanes indicated by M and U correspond to
the products amplified by MSP primer sets specific for methylated and unmethylated DNA, respectively. In vitro methylated DNA (IVD)
and normal human peripheral lymphocytes (NL) were used as positive and negative methylation controls, respectively. (A) MSP of
CRABP2 R1. (B) MSP of CRABP2 R2. (C) MSP of MX1.
Table 2. Relationship between Methylation Analyses of CRABP2 and MX1 and Clinicopathological Variables in HNSCC Patients.
Variables Category CRABP2 R1,* n (%) CRABP2 R2,* n (%) MX1,* n (%)
Unmethylated Methylated P Unmethylated Methylated P Unmethylated Methylated P
Age ≤53 26 (44.07) 23 (29.49) .078 47 (38.52) 2 (14.29) .074 29 (40.85) 20 (30.30) .198
>53 33 (55.93) 55 (70.51) 75 (61.48) 12 (85.71) 42 (59.15) 46 (69.70)
Tumor site Oral cavity 29 (49.16) 34 (43.04) .010† 58 (47.15) 4 (28.57) .097 39 (54.17) 24 (36.36) .095
Larynx 15 (25.42) 8 (10.13) 22 (17.89) 1 (7.14) 9 (12.50) 14 (21.21)
Hypopharynx 15 (25.42) 37 (46.84) 43 (34.96) 9 (64.29) 24 (33.33) 28 (42.43)
Tumor size T1 + T2 14 (25.00) 20 (26.32) .864 30 (25.42) 4 (30.77) .676 13 (18.31) 21 (34.43) .035†
T3 + T4 42 (75.00) 56 (73.68) 88 (74.58) 9 (69.23) 58 (81.69) 40 (65.57)
Lymph nodes N0 10 (17.54) 16 (21.33) .588 21 (17.80) 5 (38.46) .076 15 (21.13) 11 (18.03) .656
N+ 47 (82.46) 59 (78.67) 97 (82.20) 8 (61.54) 56 (78.87) 50 (81.97)
Grade 1 11 (19.64) 25 (34.25) .184 34 (29.57) 2 (15.38) .595 21 (31.34) 15 (24.19) .563
2 36 (64.29) 39 (53.42) 65 (56.52) 9 (69.23) 36 (53.73) 39 (62.90)
3 9 (16.07) 9 (12.33) 16 (13.91) 2 (15.38) 10 (14.93) 8 (12.90)
Vascular invasion No 35 (60.34) 51 (68.92) .305 76 (64.41) 10 (76.92) .367 40 (57.14) 45 (72.58) .055
Yes 23 (39.66) 23 (31.08) 42 (35.59) 3 (23.08) 30 (42.86) 17 (27.42)
Lymphatic permeation No 49 (84.48) 64 (87.67) .599 100 (84.75) 12 (100) .145 57 (82.61) 56 (90.32) .200
Yes 9 (15.52) 9 (12.33) 18 (15.25) 0 12 (17.39) 6 (9.68)
Perineural infiltration No 27 (46.55) 42 (57.53) .211 60 (51.28) 9 (69.23) .219 38 (55.07) 31 (50.00) .562
Yes 31 (53.45) 31 (42.47) 57 (48.72) 4 (30.77) 31 (44.93) 31 (50.00)
R1 indicates region 1; R2, region 2.
*Percentages considering cases with complete information.
†Statistically significant.
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a statistically significant association was found between tumor site and
CRABP2 hypermethylation in region 1 (P = .010). It was observed
that hypopharynx tumors showed a higher frequency of methylation
(37/52 or 71.2%) when compared with the other tumor sites. Kaplan-
Meier analysis was then used to estimate the relationship between the
methylation status of the CRABP2 gene with overall and disease-free
survival. No difference in terms of overall or disease-free survival was
observed between patients with or without CRABP2 hypermethylation
in their primary tumors.
Hypermethylation in the 5′ region of the MX1 gene was detected
in 45.0% (63/140) of the HNSCC patients. Similar to what was ob-
served for CRABP2, no MX1 hypermethylation was detected in nor-
mal lymphocytes. A statistically significant association was observed
between MX1 hypermethylation and tumor size (P = .035) and a
marginal association with vascular invasion (P = .055; Table 2). How-
ever, as for CRABP2, no difference in terms of overall or disease-free
survival was observed between patients that did or did not show MX1
hypermethylation in primary tumors.
CRABP2 Protein Expression in HNSCC Primary Tumors
CRABP2 protein expression was then analyzed in HNSCC tumors
by immunohistochemistry using a TMA containing 75 HNSCC sam-
ples. As shown in Figure 4A, CRABP2 protein immunostaining was
detected in the morphologically normal epithelium samples used as
controls, more intense staining being detected in the suprabasal (post-
mitotic) epithelial cells. Among the 75HNSCC samples, 8 cases (11%)
were negative, 37 cases (51%) were weakly positive, and 28 cases (38%)
were strongly positive (Figure 4, B–D). Two samples did not con-
tain representative sections of the tumor tissue and were not con-
sidered in the analysis. For all further analysis, weakly and strongly
positive tumors were treated as a single group with positive CRABP2
protein expression.
We then analyzed the possible association between the expression
of CRABP2 protein and clinicopathological variables. As shown in
Table 3, a statistically significant association was observed between
CRABP2 staining and increased tumor size (T3 + T4; P = .029)
and absence of lymphatic permeation (P = .014). Univariate analysis
was used to estimate the association between CRABP2 protein ex-
pression and overall or disease-free survival. No difference in terms of
overall survival was observed with CRABP2 protein expression. Inter-
estingly, our data show that an absence of CRABP2 expression was as-
sociated with a worse disease outcome because patients whose tumors
were negative for CRABP2 expression had a higher risk of locoregional
recurrence or distant metastasis than patients with CRABP2-positive
tumors (log-rank test, P = .0531; Figure 5). In the Cox regression uni-
variate model, CRABP2 protein expression showed a protective hazard
ratio of 0.40 (95% confidence interval, 0.1-1.0). However, in the mul-
tivariate analysis, CRABP2 protein expression was not shown to be an
independent prognostic factor for disease-free survival owing to the
small number of CRABP2-negative tumors or to the presence of con-
founding variables such as tumor size and site and the occurrence of
lymphatic permeation.
Discussion
Treatment with 5Aza-dC in combination with histone deacetylase in-
hibitors has been widely used to reactivate epigenetically silenced
Figure 4. CRABP2 protein immunostaining patterns. Representative immunostainings of (A) morphologically normal epithelium and (B–D)
HNSCC samples for CRABP2. Chromogenic detection (brown precipitate) counterstained with hematoxylin. Original magnifications: A,
×200 (A); B–D, ×400. Staining was scored as negative (B), weakly positive (C), or strongly positive (D).
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genes in cell lines from several types of tumor [31–35]. Although
this approach can lead to secondary effects on gene expression, it
seems to be very efficient compared with alternative strategies in
which CpG island arrays are hybridized with genomic DNA digested
with methylation-sensitive restriction enzyme [15,36] because it re-
lies directly on the reactivation of gene expression rather than on the
presence of a CpG island.
In the present study, we have used 5Aza-dC to identify genes puta-
tively silenced by DNA hypermethylation. Histone deacetylase inhib-
itors were not used because previous studies using similar strategies
have demonstrated that most genes are reactivated by high-dose
5Aza-dC treatment, and only a small subset of genes is induced by
the synergistic treatment with demethylating agents and deacetylase
inhibitors [32,33].
To evaluate changes in gene expression induced by 5Aza-dC treat-
ment, we used a combination of RaSH and cDNA microarray analysis.
The RaSH methodology has been extensively used in the identification
of differentially expressed genes, and in our study, it was used in an
attempt to enrich the cDNA microarray for 5Aza-dC reactivated genes
and not limit our analysis to a set of predefined genes represented in
commercial arrays. Two RaSH cDNA libraries were constructed: 5Aza-
dC tester and mock tester. The mock tester library was constructed in
an attempt to identify false-positive genes that were found in both
cDNA libraries and as a control of the subtraction efficiency. We iden-
tified 415 known genes of which only 65 were present in both RaSH
libraries, indicating a high subtraction efficiency. In addition, we were
able to identify 181 genes putatively induced by 5Aza-dC in the FaDu
cell line, and 151 of these genes were spotted on the microarray plat-
form and analyzed for gene reactivation in three additional HNSCC
cell lines. Using this combined approach, we identified 78 genes in-
duced on treatment and selected 35 genes, induced in at least two
of the cell lines and which contained a CpG island at the 5′ region
for technical validation by qRT-PCR. Gene expression increased at
least three-fold on 5Aza-dC treatment in 3 of the 35 genes analyzed
(CRABP2, MX1, and SLC15A3) and 2 of them (CRABP2 and MX1)
were indeed hypermethylated in the cell lines used in this study. MSP
was then used to examine the DNA methylation status of CRABP2
and MX1 in a set of 140 primary HNSCCs. MSP primers were de-
signed to target the most frequently methylated CpG dinucleotides
and those with a direct correlation with mRNA expression as revealed
by bisulfite sequencing of the tumor cell lines. Because the CpG-rich
region located at the 5′ region of CRABP2 contains 22 CpG dinucleo-
tides, two primer pairs (R1 and R2) were designed for MSP analysis of
CRABP2 in primary tumors. Unfortunately, owing to the higher GC
content of the 5′ region of the MX1 gene, we were able to design a
single primer pair for MSP analysis of MX1. CRABP2 hypermethyla-
tion was specifically detected in 56.4% and in 10.0% of the tumors
when reactions were carried out with R1 and R2 primers, respectively.
The difference in the methylation frequencies observed for different
primer pairs is expected because MSP primers were placed at different
CpG dinucleotides. MX1 hypermethylation was specifically detected
in 45.0% of primary HNSCCs. Taken together, these results suggest
that CRABP2 andMX1mRNA expression is regulated by DNA meth-
ylation and that CRABP2 and MX1 hypermethylation is frequent
among HNSCCs. Interestingly, CRABP2 (R1) or MX1 hypermethyla-
tion showed statistically significant association with tumor site or tu-
mor size, respectively. In the case of CRABP2, hypopharynx tumors
showed a higher frequency of promoter methylation when compared
with the other tumor sites.
The human MX1 (myxovirus resistance 1) gene, also named IFI78
(interferon-inducible protein p78), encodes a member of the dynamin
superfamily of large GTPases, which mediates vesicle trafficking and
organelle homeostasis [37]. Similarly to other Mx proteins, human
MX1 has antiviral activities against several RNA viruses and is tran-
scriptionally induced by interferon through the JAK/STAT pathway
[38]. MX1 is upregulated in cells of some Fanconi anemia comple-
mentation groups, which may be related to phenotypic features of this
disease, particularly bone marrow failure [23]. MX1 is downregulated
in prostate carcinomas [39] and methylated in acute myeloid leukemia
cells [40], which provide a potential link between MX1 silencing and
tumorigenesis. Supporting this link are the observations by Mibayashi
et al. [41] that MX1 promotes cell death induced by apoptotic stimuli.
Therefore, low levels of MX1 protein might contribute to apoptosis
resistance during cancer development.
Figure 5. Kaplan-Meier disease-free survival estimates from 73 pa-
tients for CRABP2 expression. Continuous and dashed lines depict
patients with positive (weak and strong) or negative CRABP2 ex-
pression (P = .0531), respectively.
Table 3. Relationship between CRABP2 Protein Expression and Clinicopathological Variables in
HNSCC Patients.
Variables Category CRABP2,* n (%) P
Negative Positive
Age ≤53 1 (50.00) 13 (55.38) >.999
>53 7 (50.00) 52 (44.62)
Tumor site Oral cavity 3 (37.50) 20 (30.77) NA
Larynx 4 (50.00) 26 (40.00)
Hypopharynx 1 (12.50) 19 (29.23)
Tumor size T1 + T2 5 (71.43) 17 (29.82) .029†
T3 + T4 2 (28.57) 40 (70.18)
Lymph nodes N0 5 (62.50) 56 (91.80) .075
N+ 3 (37.50) 5 (8.20)
Histologic grade 1 3 (37.5) 22 (33.85) NA
2 5 (62.5) 36 (55.38)
3 0 7 (10.77)
Vascular invasion No 6 (75.00) 50 (80.65) .707
Yes 2 (25.00) 12 (19.35)
Lymphatic permeation No 2 (25.00) 43 (69.35) .014†
Yes 6 (75.00) 19 (30.65)
Perineural infiltration No 6 (75.00) 34 (54.84) .278
Yes 2 (25.00) 28 (45.16)
NA indicates not applied.
*Percentages considering cases with complete information.
†Statistically significant.
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CRABP2 (cellular retinoic acid binding protein 2) encodes a small
protein (15 kDa) harboring a lipocalin domain involved in retinoic
acid (RA) binding [42,43]. CRABP2 binds to all-trans RA in the
cytoplasm, which triggers its nuclear targeting to associate with RA
receptors (RARs). Owing to the poor water solubility of RA, its bind-
ing by CRABP2 allows the intracellular RA levels and availability to
increase [44]. The association between CRABP2 and RAR in the nu-
cleus enables direct channeling of RA and increases the RAR-RXR
heterodimer transcriptional activity at RA-responsive sites [44].
RA and its derivatives (retinoids) are responsible for the regulation
of multiple biologic processes, such as embryogenesis, apoptosis, cell
proliferation, and differentiation [45]. Several authors have described
retinoids as useful pharmaceuticals for the prevention and treatment
of various types of human cancer. These studies demonstrated their
efficiency in the treatment of tumors of head and neck [46,47], lung
[48], skin [49], breast [50], and also of acute promyelocytic leukemia
[51]. However, development of RA resistance frequently occurs [52].
Importantly, two major RA pathways were described as responsible
for the antiproliferative and proliferative effects observed, respectively:
the classic CRABP2/RAR and, more recently described, the FABP5/
PPARβ/δ [53]. Therefore, both endogenous and exogenous retinoids
may only inhibit tumor growth if the RAR pathway is predominant
in the tumor cells, and this idea is supported by data showing that
diverting RA from PPARβ/δ to RAR is sufficient to overcome RA
resistance of mammary carcinomas [54]. In a related manner, abnor-
malities in the expression or in the function of retinoid receptors, par-
ticularly the suppression of RARB expression, have been found in
several types of cancer, including premalignant oral lesions [55] and
HNSCC [56,57]. Interestingly, CRABP2 mRNA and protein levels
were shown to be downregulated in carcinoma cells, relative to normal
glandular cells, in the prostate [58,59]. Also, CRABP2 was identified
as downregulated in an oligomicroarray analysis of genes related to
lymph node metastasis in esophageal squamous cell carcinoma [60].
More recently, CRABP2 expression was demonstrated to be suppressed
as a result of promoter DNA methylation in non–small cell lung
tumor [61].
Finally, in confirmation that CRABP2 is an important component
of the antiproliferative effects of the RAR pathway in response to RA,
it was shown that CRABP2 induces apoptosis in MCF-7 mammary
carcinoma cells because of the induction of transcription of cell cycle–
regulating genes [62,63] and that overexpression of CRABP2 in the
HaCaT keratinocyte cell line significantly increased tumor necrosis
factor α–induced apoptosis [53]. The correlation of CRABP2 protein
with the antiproliferative effect of RA and the induction of apoptosis
in various cells are in agreement with the results of our study showing
that CRABP2 expression loss leads to survival disadvantage.
In the present study, we have demonstrated for the first time that
CRABP2 and MX1 mRNA expression is regulated by DNA meth-
ylation and that hypermethylation of both genes is frequent among
HNSCC. Although a direct correlation between CRABP2 hyper-
methylatin and absence of protein expression was not directly evalu-
ated in the present work, we observed similar frequencies for both
CRABP2 hypermethylation (region 2 – 10.2%) and absence of
CRABP2 protein (11.0%) in different sets of HNSCC samples, sug-
gesting that DNA hypermethylation might also affect CRABP2 pro-
tein levels. Moreover, a statistically significant association between
absence of CRABP2 protein and lower survival rates was observed
in our study, suggesting that CRABP2 could be used as a prognostic
biomarker for patients with HNSCC.
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Table W1. List of the 181 Reactivated Genes after 5Aza-dC Treatment Identified by RaSH
cDNA Library.
Sequence Official Symbol CpG Island Spotted in Array
CV341138 — Yes Yes
NM_000700 ANXA1 No Yes
NM_001008897 TCP1 Yes Yes
NM_002462 MX1 Yes Yes
NM_005562 LAMC2 No Yes
NM_005347 HSPA5 Yes Yes
NM_004509 SP110 Yes No
NM_005610 RBBP4 Yes Yes
NM_001001977 ATP5E Yes Yes
NM_022073 EGLN3 Yes Yes
NM_006476 ATP5L Yes Yes
NM_002893 RBBP7 Yes No
NM_001799 CDK7 Yes Yes
NM_016237 ANAPC5 Yes Yes
NM_002463 MX2 Yes Yes
NM_001852 COL9A2 Yes No
NM_022121 PERP Yes Yes
NM_001012456 SEC61G Yes Yes
NM_002535 OAS2 Yes No
NM_015013 AOF2 Yes Yes
NM_006135 CAPZA1 Yes Yes
NM_018835 RC3H2 Yes No
NM_144596 TTC8 Yes No
NM_002227 JAK1 No Yes
NM_014352 POU2F3 Yes Yes
NM_004923 MTL5 Yes Yes
NM_003406 YWHAZ Yes Yes
NM_001007074 RPL32 Yes Yes
NM_033407 DOCK7 Yes No
NM_001686 ATP5B Yes Yes
NM_017688 BSPRY Yes Yes
NM_000979 RPL18 Yes No
NM_005056 JARID1A No Yes
NM_020675 SPC25 Yes Yes
NM_004371 COPA Yes No
NM_012420 IFIT5 Yes Yes
NM_019606 MEPCE Yes Yes
NM_015091 FAM179B Yes Yes
NM_014612 FAM120A Yes No
NM_139266 STAT1 Yes Yes
NM_014969 WDR47 Yes Yes
NM_006004 UQCRH Yes Yes
NM_006819 STIP1 Yes Yes
NM_004487 GOLGB1 Yes Yes
NM_002421 MMP1 No No
NM_006603 STAG2 Yes Yes
NM_015340 LARS2 Yes Yes
NM_000602 SERPINE1 No Yes
NM_198076 FAM36A Yes Yes
NM_003746 DYNLL1 Yes Yes
NM_005782 THOC4 Yes Yes
NM_018660 ZNF395 Yes Yes
NM_003792 EDF1 Yes Yes
NM_005381 NCL Yes Yes
NM_005762 TRIM28 Yes Yes
NM_002231 CD82 Yes Yes
NM_002797 PSMB5 No Yes
NM_001748 CAPN2 Yes No
NM_001009925 C20orf30 Yes Yes
NM_000646 AGL Yes Yes
NM_183356 ASNS Yes Yes
NM_005100 AKAP12 Yes Yes
NM_006421 ARFGEF1 Yes No
NM_198829 RAC1 Yes Yes
NM_006931 SLC2A3 No Yes
NM_000366 TPM1 Yes Yes
NM_005365 MAGEA9 No Yes
NM_006815 TMED2 Yes Yes
NM_022754 SFXN1 Yes Yes
NM_004755 RPS6KA5 Yes Yes
NM_015382 HECTD1 Yes No
NM_005243 EWSR1 Yes Yes
Table W1. (continued )
Sequence Official Symbol CpG Island Spotted in Array
NM_004130 GYG1 Yes Yes
NM_153649 TPM3 Yes Yes
NM_021101 CLDN Yes Yes
NM_006549 CAMKK2 Yes Yes
NM_001175 ARHGDIB No Yes
NM_002673 PLXNB1 Yes Yes
NM_198147 LOC116236 Yes Yes
NM_014758 SNX19 Yes Yes
NM_016565 CHCHD8 Yes Yes
NM_020914 RNF213 Yes No
NM_000576 IL1B No Yes
NM_005388 PDCL Yes No
NM_001080 ALDH5A1 Yes Yes
NM_014611 MDN1 Yes No
NM_015509 NECAP1 Yes Yes
NM_003932 ST13 Yes Yes
NM_002274 KRT13 No Yes
NM_005789 PSME3 Yes Yes
NM_182972 IRF2BP2 Yes No
NM_004859 CLTC Yes Yes
NM_133337 FER1L3 Yes Yes
NM_178868 CMTM8 Yes Yes
NM_018043 ANO1 Yes Yes
NM_003405 YWHAH Yes Yes
NM_016816 OAS1 Yes Yes
NM_001457 FLNB Yes Yes
NM_003670 BHLHB2 Yes Yes
NM_014014 ASCC3L1 Yes No
NM_002094 GSPT1 Yes No
NM_002080 GOT2 Yes Yes
NM_005113 GOLGA5 Yes Yes
NM_032547 SCOC Yes Yes
NM_000526 KRT14 No No
NM_203459 CAMSAP1L Yes Yes
NM_030920 ANP32E Yes Yes
NM_015575 GIGYF2 Yes Yes
NM_005744 ARIH1 Yes Yes
NM_032565 EBPL Yes Yes
NM_177423 PPFIA1 Yes Yes
NM_000989 RPL30 Yes Yes
NM_014752 SPCS2 Yes Yes
NM_201517 H2AFV Yes Yes
XM_031689 — Yes Yes
NM_031430 RILP Yes No
NM_213646 WARS Yes No
NM_001975 ENO2 Yes No
NM_032940 POLR2C Yes Yes
NM_032366 C16orf13 Yes Yes
NM_024881 SLC35E1 Yes Yes
NM_005389 PCMT1 Yes Yes
NM_020899 ZBTB4 Yes Yes
NM_002822 TWF1 Yes Yes
NM_016582 SLC15A3 Yes Yes
NM_016286 DCXR Yes Yes
NM_001614 ACTG1 Yes Yes
NM_001878 CRABP2 Yes Yes
NM_144570 HN1L Yes Yes
NM_002272 KRT4 No Yes
NM_001539 DNAJA1 Yes Yes
NM_018156 VPS13D Yes Yes
NM_001005340 GPNMB Yes Yes
NM_003039 SLC2A5 Yes Yes
NM_003467 CXCR4 Yes Yes
NM_000661 RPL9 Yes Yes
NM_014831 LBA1 Yes No
NM_017830 OCIAD1 Yes Yes
NM_007146 VEZF1 Yes Yes
NM_016091 EIF3EIP Yes Yes
NM_001331 CTNND Yes No
NM_013230 CD24 Yes Yes
NM_005556 KRT7 Yes Yes
NM_002211 ITGB1 Yes No
NM_031899 GORASP1 Yes Yes
Table W1. (continued )
Sequence Official Symbol CpG Island Spotted in Array
NM_003972 BTAF1 Yes Yes
NM_016284 CNOT1 Yes Yes
NM_006362 NXF1 Yes Yes
NM_006018 GPR109B No Yes
NM_181777 UBE2A Yes Yes
NM_006306 SMC1A Yes Yes
NM_013236 ATXN10 Yes Yes
NM_015384 NIPBL Yes Yes
NM_002828 PTPN2 Yes No
NM_018127 ELAC2 Yes Yes
NM_002880 RAF1 Yes Yes
NM_001008493 ENAH Yes Yes
NM_025137 SPG11 Yes Yes
BC038574 — Yes Yes
NM_003376 VEGFA Yes No
NM_001025 RPS23 Yes No
CV571660 — Yes Yes
CV411881 — Yes Yes
AL523333 — Yes Yes
NM_005121 MED13 Yes Yes
NM_016072 GOLT1B Yes Yes
NM_004966 HNRPF Yes Yes
NM_015630 EPC2 Yes Yes
NM_001002857 ANXA2 Yes Yes
NM_016520 C9orf78 Yes Yes
NM_006472 TXNIP No Yes
NM_003324 TULP3 Yes Yes
NM_201281 MTMR2 Yes Yes
NM_006796 AFG3L2 Yes Yes
NM_005358 LMO7 Yes Yes
BC027471 — Yes Yes
BM685726 — Yes Yes
NM_182926 KTN1 Yes Yes
NM_001087 AAMP Yes Yes
NM_001008844 DSP Yes Yes
AW105461 — Yes Yes
Table W2. Validation of Gene Expression Reactivation by qRT-PCR in 5Aza-dC–Treated
HNSCC Cell Lines.
Official Symbol Cell Lines
FaDu UM-SCC-14A UM-SCC-17A UM-SCC-38A
AAMP 1.7 1.7 ND ND
ACTG1 ND ND 0.8 0.6
AFG3L2 ND ND 1.0 0.5
ASNS ND ND 1.1 0.3
ATP5E 0.8 1.7 1.6 ND
ATXN10 ND ND 0.9 0.4
CAPZA1 ND 2.5 1.7 ND
CLDN1 1.9 2.4 ND ND
CRABP2 4.6 1.9 1.7 0.4
DCXR ND ND 1.3 1.1
EIF3EIP ND ND 1.0 0.8
EPC2 1.3 ND ND 0.7
MEPCE 0.9 ND 1.5 1.7
GOT2 0.6 1.1 ND ND
HNRPF ND ND 0.8 0.5
KTN1 ND ND 1.2 2.7
MED13 1.3 1.8 ND ND
MX1 22.4 4.5 ND 0.2
OCIAD1 1.1 ND 1.4 0.7
PCMT1 0.9 ND 1.2 ND
PERP 2.1 1.7 ND ND
PLXNB1 1.8 ND ND 0.3
PSME3 ND ND 1.0 0.6
RAC1 1.3 ND 1.1 ND
RAF1 ND ND 1.2 1.1
RPL30 ND 1.3 1.1 0.6
SFXN1 0.7 ND 1.3 0.6
SLC15A3 7.3 2.2 1.0 3.0
SPG11 1.0 2.0 1.0 ND
STAG2 1.4 ND 1.9 1.8
THOC4 ND ND 0.8 0.8
TNRC15 0.8 ND ND 0.7
UQCRH ND 1.6 1.3 ND
WDR47 1.5 ND 1.6 0.4
YWHAH ND ND 0.9 1.0
ND indicates not determined.
Table W3. Distribution of the HNSCC Cases According to Demographic, Lifestyle, and Clinico-
pathological Variables.
Variables Category TMA, n (%) MSP, n (%)
Age ≤53 14 (19.18) 51 (36.43)
>53 59 (80.82) 89 (63.57)
Tumor site Oral cavity 23 (30.67) 64 (45.71)
Larynx 31 (41.33) 24 (17.14)
Hypopharynx 21 (28.00) 52 (37.14)
Tumor size T1 + T2 22 (33.85) 34 (25.37)
T3 + T4 43 (66.15) 100 (74.63)
Lymph nodes N0 8 (11.43) 26 (19.40)
N+ 62 (88.57) 108 (80.60)
Grade 1 25 (34.24) 36 (27.48)
2 41 (56.16) 77 (58.78)
3 7 (9.60) 18 (13.74)
Vascular invasion No 57 (79.17) 115 (86.47)
Yes 15 (20.83) 18 (13.53)
Lymphatic permeation No 46 (63.89) 87 (64.93)
Yes 26 (36.11) 47 (35.07)
Perineural infiltration No 40 (55.56) 69 (51.88)
Yes 32 (44.44) 64 (48.12)
Table W4. Sequence and Concentration of the Primer Pairs Used in the qRT-PCR Validation of
Gene Induction.
Official Symbol Sense Sequence (5′ → 3′) μM
AAMP Forward CACCTTTGCATTGCACTCAG 0.4
Reverse TATGGCCTGCACACTCAAAG
ACTG1 Forward AGCCTTCCTTCCTGGGTATG 0.5
Reverse TGTTGGCGTACAGGTCTTTG
AFG3L2 Forward ACGAGGTGGCAAGAAAGATG 0.4
Reverse ATGACTCCACCCCAGAACAG
ASNS Forward AAGACAGCCCCGATTTACTG 0.5
Reverse AGAGCCTGAATGCCTTCCTC
ATP5E Forward TGGCAGCAACGTAAAAATTG 0.4
Reverse ACATGTGCCCACACATCTTC
ATXN10 Forward GCGAGTGGAACAGGAATCTC 0.5
Reverse AGTTCTGGGAAAGCATGCAC
CAPZA1 Forward TCGGATGAGGAGAAGGTACG 0.5
Reverse CCCTTCCCTGAGGAGATTG
CLDN1 Forward GGTGCAGAAGATGAGGATGG 0.4
Reverse CATTGACTGGGGTCATAGGG
CRABP2 Forward GACCTCGTGGACCAGAGAACTG 0.4
Reverse CCTGGTGCACACAACGTCAT
DCXR Forward GGCCTTTGACAGATCCTTTG 0.5
Reverse AGCACTGGCTGGAGACATTC
EIF3EIP Forward ACTACCAGGCCATCAAGGTG 0.5
Reverse GATGGCATCCTGGTAACGAC
EPC2 Forward GCAAGGACATGCCTGATCTC 0.4
Reverse TTGCTGTGCTGAAATTGCTC
GOT2 Forward AATGTTTGCCTCTGCCAATC 0.4
Reverse CATCCGCATCTTTGCAGAC
HNRPF Forward GCCTGGTAGCAACAGAAACC 0.5
Reverse CAGGTGATCTTGGGTGTGG
KTN1 Forward GTTTCCCCAGAAACGGAGTC 0.5
Reverse TGTGAGCTGTTGGTTTACCG
MED13 Forward TGAAGAGCATATCACCCTTGC 0.4
Reverse TTGAATGCCTGTCCTGTGAG
MEPCE Forward CAACCCTGGTCGTCGTATG 0.4
Reverse CTGGCTTCAATTGGATTCG
MX1 Forward CAATCAGCCTGCTGACATTG 0.4
Reverse TGTCTCCTGCCTCTGGATG
OCIAD1 Forward GAATGGGAGGGCTGATTTTC 0.4
Reverse TGCATTCTGCGAAGACTCTC
PCMT1 Forward CTACAGACCGCTCCCACTATG 0.6
Reverse GGAGCACTGATTGTTGCTTG
PERP Forward TACGAGGAGGGCTGTCAGAG 0.4
Reverse GGCGAAGAAGGAGAGGATG
PLXNB1 Forward TGGTTGCAAGCCATCAGAG 0.4
Reverse CTCTTGCAGGAGGGTCTGG
PSME3 Forward CCAAGGAACCAAGGTGTTTG 0.5
Reverse TGGGAATCAGGAGCTGTACC
RAC1 Forward TGCTTTTCCCTTGTGAGTCC 0.4
Reverse ATGGGAGTGTTGGGACAGTG
RAF1 Forward GCCGAACAAGCAAAGAACAG 0.5
Reverse AACACTGCACAGCACTCTGG
RPL30 Forward CCTGGGGTACAAGCAGACTC 0.4
Reverse TGATGGACACCAGTTTTAGCC
SFXN1 Forward GCAAGTTGTCGTGTCCAGGATT 0.6
Reverse TTCCAAAGTGTTCATAATGAATGG
SLC15A3 Forward AAGCTCGCTCTCCAAAACTG 0.4
Reverse GCACATTGACGGTCTCTGG
SPG11 Forward TCTCCCCAGGATAAGTCCAG 0.4
Reverse GAGGGCTTCAGGGGAATATG
STAG2 Forward AAACCAAAAGCAAGGCAAAG 0.4
Reverse GGTTTTCCTCCTCCATTTCC
THOC4 Forward CTCAGACGCCGATATTCAGG 0.5
Reverse CTCAAAGTGCACGTCTGCTG
TNRC15 Forward CTCCAGGAGGAACCCCTTC 0.6
Reverse TCCTCCTCGTCCTGTCAATC
UQCRH Forward CGGAGGAGCTCTTTGACTTC 0.5
Reverse TGCCCAGATGATGAAGACTG
WDR47 Forward CCAGGGGTACAAAACCTCAG 0.4
Reverse GATAGGCCTCTGTGCATCAAC
YWHAH Forward GCGGTGACAGAGCTGAATG 0.5
Reverse TGGTTTTCTGCTCAATGCTG
